Daniel Landa
Cardiovascular Disease · Fullerton, CANPI 1174527139
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 146 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,269 and has fallen 98.9% since, to $14 in 2024. That places this record below the midpoint for cardiovascular disease clinicians in CA, where the typical reported total is $2,142.
Across 146 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$601
- Sanofi-aventis U.S. LLC$417
- Amgen$273
- Johnson & Johnson$215
- E.r. Squibb & Sons, L.L.C.$211
- Abbott$179
- plus $735 from 14 others
What the payments were for
- Food & beverage$2,57998%
- Education$522%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 37 | $601 |
| Sanofi-aventis U.S. LLC | 28 | $417 |
| Amgen | 19 | $273 |
| Johnson & Johnson | 14 | $215 |
| E.r. Squibb & Sons, L.L.C. | 12 | $211 |
| Abbott | 4 | $179 |
| Medtronic | 4 | $139 |
| Merck | 2 | $93 |
| Novartis | 4 | $79 |
| Boehringer Ingelheim | 4 | $77 |
| Regeneron Healthcare Solutions, Inc. | 2 | $65 |
| Amarin Pharma, Inc. | 3 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $52 |
| Boston Scientific | 2 | $50 |
| Arbor Pharmaceuticals, Inc. | 3 | $38 |
| Impulse Dynamics (USA) Inc. | 1 | $21 |
| AstraZeneca | 1 | $18 |
| Edwards Lifesciences | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$205
- Optis Coronary Imaging System$113
- ELIQUIS$108
How this compares
$2,631 in reported general payments places this provider in the 50th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Fullerton
- Ted LoveHillsborough$102.8M
- Paul KurthSanta Barbara$6.1M
- Jason RogersSacramento$4.4M
- Matthew BudoffTorrance$3.6M
- Eric Topolla Jolla$2.2M
- Cathleen Bairey-MerzLos Angeles$1.2M
- Gagan SinghSacramento$1.2M
- Pam Taubla Jolla$1.2M
- Wilber SuStanford$1.1M
- Thomas SmithSacramento$942K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.